Literature DB >> 19884628

Cost-effectiveness of biologics as first-line treatment of rheumatoid arthritis: case closed?

Maarten Boers.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19884628     DOI： 10.7326/0003-4819-151-9-200911030-00013

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN： 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  7 in total

1.  Novel approaches to incorporating pharmacoeconomic studies into phase III clinical trials for Alzheimer's disease.

Authors:  H Fillit; J Cummings; P Neumann; T McLaughlin; P Salavtore; C Leibman
Journal:  J Nutr Health Aging       Date:  2010-10       Impact factor: 4.075

Review 2.  Certolizumab pegol: a new biologic targeting rheumatoid arthritis.

Authors:  Aarat M Patel; Larry W Moreland
Journal:  Expert Rev Clin Immunol       Date:  2010-11       Impact factor: 4.473

3.  Devolving therapeutic pyramids.

Authors:  Stephen B Hanauer
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-03       Impact factor: 46.802

4.  Is there a place for nonbiological drugs in the treatment of rheumatoid arthritis?

Authors:  Alejandro Balsa; Miriam García-Arias
Journal:  Ther Adv Musculoskelet Dis       Date:  2010-12       Impact factor: 5.346

Review 5.  Interleukin-6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapy.

Authors:  Aarat M Patel; Larry W Moreland
Journal:  Drug Des Devel Ther       Date:  2010-10-01       Impact factor: 4.162

Review 6.  Management of rheumatoid arthritis: consensus recommendations from the Hong Kong Society of Rheumatology.

Authors:  Chi Chiu Mok; Lai Shan Tam; Tak Hin Chan; Gavin K W Lee; Edmund K M Li
Journal:  Clin Rheumatol       Date:  2010-11-03       Impact factor: 2.980

Review 7.  Tocilizumab in the treatment of rheumatoid arthritis and beyond.

Authors:  Anjali Shetty; Rebekah Hanson; Peter Korsten; Munir Shawagfeh; Shiva Arami; Suncica Volkov; Olga Vila; William Swedler; Abdel Naser Shunaigat; Sameer Smadi; Ray Sawaqed; David Perkins; Shiva Shahrara; Nadera J Sweiss
Journal:  Drug Des Devel Ther       Date:  2014-03-28       Impact factor: 4.162
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.